APEX BIOVENTURES ACQUISITION CORP

APEX BIOVENTURES ACQUISITION CORP, trading under the ticker PEX, was a blank-check company focused on life sciences and biotechnology acquisitions. The company filed a Form 15-12B with the Securities and Exchange Commission on June 2, 2009, formally terminating its registration under the Securities Exchange Act and ending its public reporting obligations. The deregistration marks the conclusion of PEX's lifecycle as a publicly registered vehicle. Formed during the mid-to-late 2000s biotech SPAC wave, PEX sought acquisition targets in the life sciences space during a period of significant market dislocation. Sign up at SpacDesk for complete filing records, sponsor data, and deal analytics on PEX and the broader SPAC universe.